SCHEMBL164467

SCHEMBL164467

CC(C)(Cc1ncc(-c2ccc(NC(=O)Nc3ccc(Cl)cc3Oc3ccccc3)cc2)o1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 1/20 0.52
DGAT1 O75907 2/20 0.52
CSGALNACT1 Q8TDX6 1/20 0.49
IDO1 P14902 2/20 0.41
PDGFRA P16234 1/20 0.41
KDR P35968 1/20 0.41
NPC1 O15118 2/20 0.41
GRIK1 P39086 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CLK1 P49759 1/20 0.41
RAB9A P51151 1/20 0.41
GFER P55789 1/20 0.41
IGF1R P08069 5/20 0.40
CNR1 P21554 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165000 0.94 P2RY1 (0.51) P2RY1DGAT1CSGALNACT1IDO1PDGFRA
SCHEMBL160302 0.82 SMO (0.48) DGAT1CSGALNACT1KDRNPC1MEN1
SCHEMBL163289 0.82 DGAT1 (0.64) P2RY1DGAT1CSGALNACT1IDO1PDGFRA
SCHEMBL163218 0.78 HDAC1 (0.49) KDRNPC1MEN1ALDH1A1LMNA
SCHEMBL162034 0.77 DGAT1 (0.62) P2RY1DGAT1CSGALNACT1IDO1NPC1
SCHEMBL1756348 0.77 DGAT1 (0.73) P2RY1DGAT1CSGALNACT1
SCHEMBL161215 0.76 CCNE2 (0.48) DGAT1KDRNPC1MEN1ALDH1A1
SCHEMBL161602 0.76 DGAT1 (0.62) P2RY1DGAT1CSGALNACT1IDO1PDGFRA
SCHEMBL1756209 0.76 DGAT1 (0.64) P2RY1DGAT1CSGALNACT1PDGFRAKDR
SCHEMBL162141 0.76 MEN1 (0.45) DGAT1KDRNPC1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 P2RY1 1922/4885DGAT1 1/4885CSGALNACT1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.